Intellia Therapeutics, Inc. (NTLA) Earnings Call Transcript & Summary

Good day and welcome to the Intellia Therapeutics, Inc. 2020 Annual Meeting of Stockholders. I would now like to turn the conference over to Dr. Frank Verwiel, Chairman of the company's Board of Directors, to proceed with the 2020 Annual Meeting of Stockholders. Dr. Verwiel, please go ahead.

Good morning. I'm Frank Verwiel, Chairman of the Board of Intellia Therapeutics, Inc., and I will act as Chairman of this meeting. I'm pleased to welcome you to the Intellia 2020 Annual Meeting of Stockholders. Before I call the meeting to order, I would like to introduce you to the members of our Board and our executive team who are with us today. The other members of the Board that are with us today are: Dr. Fred Cohen; Caroline Dorsa; Dr. Jean-Franois Formela; Dr. Jesse Goodman; Perry Karsen and Dr. John M. Leonard, our President and Chief Executive Officer. The other executive officers and officers of the company with us today are: Glenn Goddard, Chief Financial Officer; Dr. Nishla Keiser, Deputy General Counsel; Dr. David Lebwohl, Chief Medical Officer; Jose Rivera, General Counsel and Corporate Secretary, Dr. Andrew Schiermeier, Chief Operating Officer; and Dr. Laura Sepp-Lorenzino, Chief Scientific Officer. Mr. Rivera will act as secretary; and Dr. Keiser will act as Inspector of election for this meeting. Dr. Keiser has taken and subscribed the customary oath of office to execute her duties with strict impartiality, which will be filed with the records of this meeting. I also would like to introduce Sarah Albano from Deloitte & Touche LLP, the company's independent registered public accounting firm, who is available to respond to appropriate questions. The meeting will now officially come to order. We propose to proceed with the formal business of the meeting as set forth in the company's 2020 notice of annual meeting and proxy statement. We request that if you have questions, please submit them following the instructions providing on the virtual screen and described in the rules of conduct. Will the secretary please report, at this time, on the mailing of the notice for this meeting and the stockholder list?

Good morning. I have at this meeting, a complete list of the stockholders of record of the company at the close of business on April 20, 2020, the record date for this meeting. I also have an affidavit certifying that commencing on April 24, 2020, the notice of Internet availability of proxy materials was deposited in the United States Mail to all stockholders of record as of April 20, 2020.

Will the secretary please report at this time with respect to the existence of a quorum?

I have been informed by the Inspector of elections that proxies have been received for 44,970,193 shares, up to 51,358,723 shares of common stock outstanding on the record date, which represents approximately 87.6% of the total number of shares entitled to vote at this meeting. This constitutes a quorum for the meeting today, and we may now carry out the official business of the meeting. Are there any additional proxies to be submitted to the inspector of elections at this time?

Dr. Rivera, there have been no additional proxies submitted to me at this time.

Thank you. We will now proceed with the formal business of this meeting. The following proposals are to be considered by our stockholders at this meeting. Proposal 1 is the election of directors. Election of the following individuals nominated to serve as Class I directors for a 3-year term ending at the annual meeting of stockholders to be held in 2023: Dr. Jean-Francois Formela and Dr. Jesse Goodman. Proposal 2 is the ratification of the appointment of the Lloyd & Touche LLP as the independent registered public accounting firm of the company for the fiscal year ending December 31, 2020. Proposal 3 is the approval on a nonbinding advisory basis of the compensation of the named executive officers. Those were the final proposals for today's meeting. The secretary will now describe the voting procedures.

It is now 9:05 a.m. Eastern Time on Thursday, June 18, 2020, and the polls are now open for voting on the proposals described by the Chairman. All Intellia stockholders entitled to vote at this meeting have the ability to do so online. You do not need to vote again if you have already voted your proxy online, by telephone or by mail and do not wish to change your vote. However, if you have either not voted already or if you want to change your previous vote, you may do so now in accordance with the instructions on your virtual meeting screen and described in the rules of conduct. [Voting]

The time is now 9:06 a.m. Eastern Time, and the polls are now closed for voting.

May we have the results of the voting?

The report of the inspector of elections covering the proposals presented at this meeting is as follows: Proposal 1, for the election of the following individuals: Dr. Jan Franois Formela; and Dr. Jesse Goodman as Class I directors of the company, is carried; Proposal 2 for the ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the company, for the fiscal year ending December 31, 2020, has been approved; Proposal 3, for the approval on an advisory basis of the compensation of the named executive offers, has been approved.

Thank you. There'd be no other business to properly come before this meeting. Let us pause for a moment to compile any questions that have been submitted via the online portal regarding only the matters that have been discussed in this formal portion of the annual meeting. Will the secretary please advise if we have any questions?

We have no questions appropriately related to the purpose of the meeting.

There being no other business to properly become before this meeting, this meeting is now adjourned. Thank you for attending an Intellia Therapeutics, Inc. 2020 Annual Meeting of Stockholders.

The 2020 Annual Meeting of Stockholders has now concluded. Thank you for attending today's meeting.